What does Nicaphis do?
NICAPHIS specializes in the development and manufacturing of innovative pharmaceutical products. The company focuses on enhancing healthcare solutions through advanced research and technology. Their portfolio includes a range of medications aimed at improving patient outcomes and quality of life.
- Sectors
- Wholesalers
- Activities
- Signals
-
Reporting lossesReporting losses € -396K
The company reported a loss in the latest financial year.
Strong equityStrong equity € 53.27MStrong equity provides a buffer against setbacks.
Low riskLow risk 82.5%Good solvency (> 30%) points to long-term financial stability.
Good liquidityGood liquidity 8.51A healthy current ratio (≥ 1.5): enough current assets to cover short-term debt.
Positive cashflowPositive cashflow € 7.69MPositive operating cash flow in the latest financial year.
Positive EBITDAPositive EBITDA € 903KPositive EBITDA: operating activities are profitable.
- Investments
- Neologic 60%, Tecno Space Group 50%, Alcopa 18,28%, +1 more
Financial ratios
|
max) max = w;
}
}
const wClamped = Math.max(120, Math.min(800, max));
colWidths[''] = wClamped;
save && save();
})(event)">
|
2025
max) max = w;
}
}
const wClamped = Math.max(120, Math.min(800, max));
colWidths[''] = wClamped;
save && save();
})(event)">
|
2024
max) max = w;
}
}
const wClamped = Math.max(120, Math.min(800, max));
colWidths[''] = wClamped;
save && save();
})(event)">
|
2023
max) max = w;
}
}
const wClamped = Math.max(120, Math.min(800, max));
colWidths[''] = wClamped;
save && save();
})(event)">
|
2022
max) max = w;
}
}
const wClamped = Math.max(120, Math.min(800, max));
colWidths[''] = wClamped;
save && save();
})(event)">
|
|---|---|---|---|---|
|
€
1.21M
|
€
3.93M
|
€
1.67M
|
€
1.51M
|
|
|
€
903K
|
€
3.61M
|
€
1.38M
|
€
1.24M
|
|
|
€
6.39M
|
€
5.07M
|
€
4.25M
|
€
2.28M
|
|
|
€
53.27M
|
€
48.89M
|
€
45.17M
|
€
44.29M
|
|
|
82.46%
|
86.66%
|
83.20%
|
86.36%
|
|
|
€
9.51M
|
€
5.61M
|
€
7.65M
|
€
5.43M
|
|
|
€
14.69M
|
€
12.23M
|
€
7.15M
|
€
6.58M
|
Publications 48
All publications- Demissions, Nominations 05/01/2024
- Statuts (Traduction, Coordination, Autres Modifications, ) - Capital, Actions 16/05/2023
- Statuts (Traduction, Coordination, Autres Modifications, ) - Capital, Actions 05/02/2021
- Demissions, Nominations 05/04/2018
- Siege Social 27/02/2017
Frequently asked questions
Answers to the most common questions about Nicaphis, based on official government data and the filed annual accounts.
What is the VAT number of Nicaphis?
The VAT number of Nicaphis is BE0432.774.804.
When was Nicaphis established?
Nicaphis was founded in 09-12-1987.
What is the official address of Nicaphis?
The official address of Nicaphis is Louizalaan 551 Elsene 1050.
What is the legal form of Nicaphis?
The juridical form of Nicaphis is Public limited company (NV/SA).
What is the annual revenue of Nicaphis?
The 2025 accounts of Nicaphis do not report revenue. Smaller companies that file abbreviated accounts are not required to publish it.
What does Nicaphis do?
NICAPHIS specializes in the development and manufacturing of innovative pharmaceutical products. The company focuses on enhancing healthcare solutions through advanced research and technology. Their portfolio includes a range of medications aimed at improving patient outcomes and quality of life.
Is Nicaphis a reliable company?
Nicaphis is a registered Rechtspersoon with company number 0432.774.804 and can be verified through the official CBE database.
What is the credit limit of Nicaphis?
The estimated credit limit of Nicaphis is €3,477,020.
Is Nicaphis still active?
Nicaphis currently has the status "Normal situation" and is active.